{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:02:33Z","timestamp":1794499353805,"version":"4.9.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.semnuclmed.2026.08.006","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:36:15Z","timestamp":1787830575000},"page":"1113-1123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["FAPI PET in musculoskeletal oncology: An update and future directions"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0354-5793","authenticated-orcid":false,"given":"Anja","family":"Dietze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-3834","authenticated-orcid":false,"given":"Daniel M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-736X","authenticated-orcid":false,"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-7701","authenticated-orcid":false,"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0001","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.semnuclmed.2021.06.008","article-title":"Limitations and pitfalls of FDG-PET\/CT in infection and inflammation","volume":"51","author":"Pijl","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0002","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00259-021-05198-2","article-title":"An international expert opinion statement on the utility of PET\/MR for imaging of skeletal metastases","volume":"48","author":"Husseini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.semnuclmed.2021.06.009","article-title":"PET\/CT variants and pitfalls in bone and soft tissue sarcoma","volume":"51","author":"Benz","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109168","article-title":"The impact of infection and inflammation in oncologic (18)F-FDG PET\/CT imaging","volume":"117","author":"Rahman","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0005","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","author":"Pang","year":"2021","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0007","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.7150\/thno.40599","article-title":"FDG uptake in cancer: a continuing debate","volume":"10","author":"Peppicelli","year":"2020","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0008","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0009","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0011","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","article-title":"Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells","volume":"85","author":"Rettig","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","article-title":"Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours","volume":"55","author":"Dohi","year":"2009","journal-title":"Histopathology"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0013","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0014","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"(68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0017","article-title":"Fibroblast activation protein inhibitor (FAPI) PET: a scoping review of emerging oncologic and fibroinflammatory applications","volume":"16","author":"Panagiotidis","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0018","doi-asserted-by":"crossref","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0019","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0020","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13569-018-0095-9","article-title":"Retrospective audit of 957 consecutive (18)F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma","volume":"8","author":"Macpherson","year":"2018","journal-title":"Clin Sarcoma Res"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0022","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00259-009-1203-0","article-title":"FDG PET\/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases","volume":"36","author":"Charest","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0023","article-title":"Soft tissue tumors in adults: eSSR-approved guidelines for diagnostic imaging","volume":"19","author":"Noebauer-Huhmann","year":"2015","journal-title":"Semin Musculoskelet Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0024","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.123.267248","article-title":"(68)Ga-fibroblast activation protein inhibitor PET\/CT improves detection of intermediate and low-grade sarcomas and identifies candidates for radiopharmaceutical therapy","volume":"65","author":"Lanzafame","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0025","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","article-title":"Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT","volume":"48","author":"Koerber","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0026","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00259-022-05700-4","article-title":"Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma","volume":"49","author":"Gu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0027","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1007\/s00259-026-07904-4","article-title":"Diagnostic value of [\u2076\u2078Ga]Ga-FAPI PET imaging in patients with sarcoma","volume":"53","author":"G\u00fcneren","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.121.262096","article-title":"(68)Ga-FAPI as a diagnostic tool in sarcoma: data from the (68)Ga-FAPI PET prospective observational trial","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0029","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13139-025-00936-y","article-title":"Exploring the diagnostic and theranostic role of FAPI PET in soft tissue sarcoma: a systematic review","volume":"59","author":"Abdulrahman","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0030","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/RLU.0000000000005697","article-title":"Head-to-Head comparison between [68 Ga]Ga-DOTA.SA.FAPi and [18 F]F-FDG PET\/CT imaging in patients with Sarcoma","volume":"50","author":"Sakir","year":"2025","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0031","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","article-title":"(68)Ga-FAPI-04 vs. (18)F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer","volume":"49","author":"Ding","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0032","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/RLU.0000000000004438","article-title":"Comparison of the detection performance between FAP and FDG PET\/CT in various cancers: a systemic review and meta-analysis","volume":"48","author":"Chang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0033","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.121.262808","article-title":"Pitfalls and common findings in (68)Ga-FAPI PET: a pictorial analysis","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET","volume":"66","author":"Hope","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0036","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0037","first-page":"3279","article-title":"Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"21","author":"Oster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0038","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060156","article-title":"Multidisciplinary approach for bone metastasis: a review","volume":"10","author":"Kimura","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0040","article-title":"Comparison of PET\/CT and MRI in the diagnosis of bone metastasis in prostate cancer patients: a network analysis of diagnostic studies","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0041","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s00330-011-2221-4","article-title":"Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy","volume":"21","author":"Yang","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0042","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejrad.2016.10.014","article-title":"The role of diffusion-weighted MRI (DWI) in the differentiation of benign from malignant skeletal lesions of the pelvis","volume":"85","author":"Douis","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0043","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1258\/ar.2011.110115","article-title":"Comparison of 18F-FDG PET\/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis","volume":"52","author":"Cheng","year":"2011","journal-title":"Acta Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0044","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.7314\/APJCP.2013.14.6.3647","article-title":"Diagnostic value of 18F-FDG PET\/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis","volume":"14","author":"Liu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4184\/asj.2013.7.2.96","article-title":"(18)F-FDG PET\/CT for diagnosis of osteosclerotic and osteolytic vertebral metastatic lesions: comparison with bone scintigraphy","volume":"7","author":"Uchida","year":"2013","journal-title":"Asian Spine J"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0046","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/MNM.0000000000000479","article-title":"Comparison of 18F-FDG PET\/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors","volume":"37","author":"Al-Bulushi","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0047","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.rlu.0000218575.91735.5f","article-title":"Obscured bone metastases after administration of hematopoietic factor on FDG-PET","volume":"31","author":"Chhabra","year":"2006","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0048","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.nucmedbio.2006.09.005","article-title":"Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET\/CT","volume":"33","author":"Murata","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102896","article-title":"Emergence of cancer-associated fibroblasts as an indispensable cellular player in bone metastasis process","volume":"12","author":"Mukaida","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117426","article-title":"Superiority of (68)Ga-DOTA-FAPI-04 PET\/CT to (18)F-FDG PET\/CT in the evaluation of different cancers with bone metastases","volume":"196","author":"Guo","year":"2025","journal-title":"Bone"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0052","article-title":"Comparison of the relative diagnostic performance of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET\/CT for the detection of bone metastasis in patients with different cancers","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0053","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mednuc.2022.12.002","article-title":"Comparison of 68GA-FAPI-04 PET\/CT and 18F-FDG PET\/CT in detection of metastatic bone disease in various cancers","volume":"47","author":"Kepenek","year":"2023","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0054","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222785","article-title":"FAPI compared with FDG PET\/CT for diagnosis of primary and metastatic lung cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0055","article-title":"Head-to-head comparative study of [(68)Ga]FAPI-04 PET\/CT and [(18)F]FDG PET\/CT in assessing bone metastasis of various cancers: a systematic review and meta-analysis","volume":"16","author":"He","year":"2026","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0056","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.7150\/thno.88335","article-title":"Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis","volume":"13","author":"Ruan","year":"2023","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111302","article-title":"Head-to-head comparison of [68Ga]Ga-FAPI PET and [18F]FDG PET in the detection of bone and lymph node metastasis in various cancers: a systematic review and meta-analysis","volume":"171","author":"Wu","year":"2024","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0058","first-page":"374","article-title":"Diagnosis of bone metastasis: recent comparative studies of imaging modalities","volume":"55","author":"Talbot","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0059","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s12149-024-01935-3","article-title":"Prognostic significance of (68) Ga-FAPI PET\/CT in patients with bone metastases in various cancers","volume":"38","author":"Arak","year":"2024","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.123.266798","article-title":"(68)Ga-FAPI PET\/CT as an alternative to (18)F-FDG PET\/CT in the imaging of invasive lobular breast carcinoma","volume":"65","author":"Sahin","year":"2024","journal-title":"J Nucl Med."},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.120.258467","article-title":"(68)Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET\/CT","volume":"63","author":"Qin","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0062","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0063","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-026-02853-6","article-title":"Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Chen","year":"2026","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0064","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0065","article-title":"A systematic review of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET\/CT in the diagnostic value of malignant tumor bone metastasis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0066","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1097\/RLU.0000000000006318","article-title":"Fibroblast activation protein inhibitor theranostics in Sarcoma: current evidence and future directions","volume":"51","author":"Jafari","year":"2026","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0067","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2967\/jnumed.123.266345","article-title":"Preclinical development of PNT6555, a boronic acid-based, fibroblast activation protein-\u03b1 (FAP)-targeted radiotheranostic for imaging and treatment of FAP-positive tumors","volume":"65","author":"Poplawski","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0068","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0069","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0070","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-026-01386-0","article-title":"Theranostics in Sarcoma: a critical review of current evidence and future potential","volume":"27","author":"Appana","year":"2026","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0071","doi-asserted-by":"crossref","first-page":"744","DOI":"10.2967\/jnumed.125.271135","article-title":"(90)Y-FAPI-46 radiopharmaceutical therapy in Sarcoma and other solid tumors: an updated cohort analysis","volume":"67","author":"Lanzafame","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0072","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0073","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000006507","article-title":"FAP-targeted theranostics in advanced sarcoma: a pilot study of \u2076\u2078ga-FAPI-46 imaging and \u00b9\u2077\u2077lu-FAPI-2286 therapy","author":"Jokar","year":"2026","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0074","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2967\/jnumed.125.271031","article-title":"Initial clinical experience with [(177)Lu]Lu-RTX-2358 radiopharmaceutical therapy targeting fibroblast activation protein: biodistribution, pharmacokinetics, and dosimetry","volume":"67","author":"Glantschnig","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0075","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0076","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0077","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0078","first-page":"727","article-title":"Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0079","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0080","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-Human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0081","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.semnuclmed.2024.09.009","article-title":"Clinical explorations of [(68)Ga] Ga-FAPI-04 and [(18)F] FDG dual-tracer total-body PET\/CT and PET\/MR imaging","volume":"54","author":"Lin","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0082","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1007\/s00330-022-09321-1","article-title":"Utility of [(68)Ga]FAPI-04 and [(18)F]FDG dual-tracer PET\/CT in the initial evaluation of gastric cancer","volume":"33","author":"Miao","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0083","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS11598","article-title":"The ATLAS study: a first-in-human phase 1\/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma","volume":"44","author":"D'Angelo","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0084","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clon.2021.09.004","article-title":"Combining external beam radiation and radionuclide therapies: rationale, radiobiology, results and roadblocks","volume":"33","author":"Abbott","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1053\/j.semnuclmed.2026.08.006_bib0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.125.270465","article-title":"Current developments in combining external-beam radiotherapy and (177)Lu-labeled PSMA ligands for prostate cancer treatment","volume":"66","author":"Teunissen","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826001649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:53:45Z","timestamp":1794430425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0001299826001649"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.08.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FAPI PET in musculoskeletal oncology: An update and future directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}